Ketamine for treatment resistant depression: prospects and pitfalls

Add to your list(s) Download to your calendar using vCal

• Dr Rupert McShane, Dementia Clinical Network Lead - Oxford Academic Health Science Network; Associate Professor of Psychiatry, Department of Psychiatry, University of Oxford
• Thursday 30 November 2017, 12:30-13:30
• Seminar Room, Herchel Smith Building, Forvie Site..

If you have a question about this talk, please contact Nicholas Morgan.

Ketamine is a potent acute antidepressant in some patients with otherwise resistant depression. The time to relapse is variable, but usually 1-2 weeks. The scalability of repeated ketamine depends on the route of administration and on the durability of continued response. What influence can concomitant psychotherapy or other glutamateric drugs have on this? Because it is a licensed drug, clinical experience is moving faster than research, which holds risks as well as opportunities. Based on our experience of 1000 infusions in 100 patients, I will illustrate the variety of trajectories shown by daily mood monitoring. I will suggest that ketamine and related compounds have the potential to be as disruptive to how we practice psychiatry as ECT was in the 1930s and antipsychotics were in the 1960s.

The speaker is Associate Professor of Psychiatry, Department of Psychiatry, University of Oxford, a consultant old age psychiatrist, and lead consultant for ECT at Oxford Health NHS Foundation Trust.

This talk is part of the Department of Psychiatry & CPFT Thursday Lunchtime Seminar Series series.

This talk is included in these lists:

• Cardiovascular Epidemiology Unit Special Seminars
• Department of Psychiatry & CPFT Thursday Lunchtime Seminar
• Department of Psychiatry talks stream
• Department of Public Health and Primary Care
• Psychology talks and events
• PublicHealth@Cambridge
• Seminar Room, Herchel Smith Building, Forvie Site.
• Yishu's list
• my List

Note that ex-directory lists are not shown.